Cyclacel Pharmaceuticals (CYCC) Insider Trading & Ownership $0.32 -0.01 (-4.11%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Cyclacel Pharmaceuticals (NASDAQ:CYCC) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.00%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$26,334.36Number OfInsiders Selling(Last 12 Months)0 Get CYCC Insider Trade Alerts Want to know when executives and insiders are buying or selling Cyclacel Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CYCC Insider Buying and Selling by Quarter Ad Porter & CompanyVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Cyclacel Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/21/2023Paul McbarronInsiderBuy1,886$3.31$6,242.66 12/21/2023Spiro George RombotisCEOBuy6,070$3.31$20,091.70 (Data available from 1/1/2013 forward) CYCC Insider Trading Activity - Frequently Asked Questions Who is on Cyclacel Pharmaceuticals's Insider Roster? The list of insiders at Cyclacel Pharmaceuticals includes Paul Mcbarron, and Spiro George Rombotis. Learn more on insiders at CYCC. What percentage of Cyclacel Pharmaceuticals stock is owned by insiders? 8.00% of Cyclacel Pharmaceuticals stock is owned by insiders. Learn more on CYCC's insider holdings. Which Cyclacel Pharmaceuticals insiders have been buying company stock? The following insiders have purchased CYCC shares in the last 24 months: Paul Mcbarron ($6,242.66), and Spiro George Rombotis ($20,091.70). How much insider buying is happening at Cyclacel Pharmaceuticals? Insiders have purchased a total of 7,956 CYCC shares in the last 24 months for a total of $26,334.36 bought. Cyclacel Pharmaceuticals Key ExecutivesMr. Spiro George Rombotis (Age 65)President, CEO & Executive Director Compensation: $612.47kMr. Paul McBarron (Age 63)Executive VP of Finance, CFO, COO, Secretary & Executive Director Compensation: $321.61kDr. Brian Schwartz M.D. (Age 62)Interim Chief Medical Officer & Director Compensation: $53kMs. Gill Christie (Age 67)Director of Human Resources Grace KimInvestor Relations Executive More Insider Trading Tools from MarketBeat Related Companies Brainstorm Cell Therapeutics Insider Trading Ensysce Biosciences Insider Trading Aytu BioPharma Insider Trading Viracta Therapeutics Insider Trading Conduit Pharmaceuticals Insider Trading CERo Therapeutics Insider Trading Soligenix Insider Trading Coeptis Therapeutics Insider Trading Eyenovia Insider Trading Adial Pharmaceuticals Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:CYCC) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYCC Stock Alerts